Skip to main content

Table 3 The primary end point results in the 18 months observational periods after 6 months inhaled GM-CSF treatment

From: Inhaled granulocyte-macrophage colony stimulating factor for mild-to-moderate autoimmune pulmonary alveolar proteinosis - a six month phase II randomized study with 24 months of follow-up

  9 months 12 months 18 months 24 months
  Control group (n = 12) Treatment group (n = 14) P value Control group (n = 13) Treatment group (n = 14) P value Control group (n = 12) Treatment group (n = 13) P value Control group (n = 11) Treatment group (n = 15) P value
Δ A-aDO2 (mmHg) 4.53 ± 7.59 8.11 ± 10.89 0.461 5.19 ± 9.72 7.02 ± 12.35 0.674 8.13 ± 15.02 7.39 ± 8.677 0.579 6.05 ± 11.14 6.61 ± 10.64 0.899
A-aDO2 (mmHg) 25.24 ± 7.05 22.16 ± 9.09 0.366 22.35 ± 6.54 23.25 ± 8.10 0.756 18.38 ± 10.50 22.24 ± 9.43 0.343 23.72 ± 9.41 23.66 ± 8.96 0.988
Δ PaO2 (mmHg) 4.29 ± 8.38 7.45 ± 11.82 0.267 2.78 ± 11.41 5.89 ± 11.91 0.496 8.13 ± 15.02 7.71 ± 8.72 0.931 6.16 ± 9.88 4.76 ± 10.72 0.741
PaO2 (mmHg) 81.08 ± 7.14 84.15 ± 8.93 0.362 81.84
±7.13
82.59 ± 7.70 0.794 86.48 ± 10.75 84.99 ± 9.76 0.721 82.95 ± 8.05 81.46 ± 10.84 0.707
  1. Abbreviations: see Table 1